about
Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? YesCharacterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura.Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease.Cryoprecipitate-reduced plasma:rationale for use and efficacy in the treatment of thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection.Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy.Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.Targeting von Willebrand factor and platelet glycoprotein Ib receptor.A Case of HIV Infection with Thrombocytopenia: Assosiation of HIV, Thrombotic Thrombocytopenic Purpura and Brucellosis.Congenital microangiopathic haemolytic anemia: a variant of thrombotic thrombocytopenic purpura?Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: a case series.Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption.Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group.Guidelines for assessing appropriateness of pediatric transfusion.Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
P2860
Q28188189-370B3B9B-B4BA-4F14-8363-088B04687ABBQ33330802-68532520-3938-49F8-B91A-9ACECE5725EFQ33335107-9D5132AB-A055-49F5-893D-998AC808F465Q33335807-B70A51D0-432E-47F5-A17F-C4A260C33A5BQ33337694-3D31A3A0-7B50-4B6D-8FBD-62D1BEA731F2Q33359746-F3C75827-DA03-4D10-84CF-CEC4F409014AQ33360121-5C7357D4-3581-4C12-AD04-F85D46AF05DFQ33364650-C4AA1635-1E34-4CBF-86FF-3EE1A365F20BQ33374294-1585A379-9F75-4298-B9C2-275EA8608D38Q33392975-842E2802-D154-42DA-9B14-FFA962DA92A1Q33400000-5618029F-0999-46DD-994E-155ED2923AFAQ33492938-3444F003-9727-4EBA-B493-69DD3076CEC8Q33498152-C4A0FFF1-034C-4B81-9985-571DE03B1060Q33499711-4BA9E986-E3AF-4EAD-B05D-280C9B9453F2Q33504909-BD64060D-8544-49AF-9895-9260629C2B1DQ34991606-C9D4A3A6-D03C-40A0-92B6-EB47376319BBQ35125769-C2D27053-F4D8-4FBB-888B-A5CAB1150253Q44168582-A5EB9AEC-13C9-4E99-B885-E4087CE6CF42
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Resistance development to fluoroquinolones in Europe.
@en
type
label
Resistance development to fluoroquinolones in Europe.
@en
prefLabel
Resistance development to fluoroquinolones in Europe.
@en
P1476
Resistance development to fluoroquinolones in Europe.
@en
P2093
Wiedemann B
Zühlsdorf MT
P304
P356
10.1016/0002-9343(89)90011-9
P407
P577
1989-11-01T00:00:00Z